

Rituximab, dexamethasone, etoposide, ifosfamide and carboplatin (R-DeVIC) in relapsed or refractory central nervous system lymphoma: a retrospective multicentre clinical study

Authors

Kudret Kama,¹ Hannes Treiber,² Alexandra Kutilina,³ Stefan Trefz,¹ Sophie Wollnitzer,⁴ Evgenii Shumilov,⁴ Juergen Finke,³ Georg Lenz,⁴ Gerald Wulf,² Lisa Kristina Isbell,³ Aslihan Aksoy,⁵ Antje Jensch,⁵ Gerald Illerhaus,¹ Julia Wendler^{1#} and Elisabeth Schorb^{3#}

¹Department of Hematology, Oncology, Stem-Cell Transplantation and Palliative Care, Klinikum Stuttgart, Stuttgart; ²Department of Hematology and Medical Oncology, Georg-August University Göttingen, Göttingen; ³Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University of Freiburg, Freiburg; ⁴Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster and ⁵Stuttgart Cancer Center – Tumorzentrum Eva Mayr-Stihl, Klinikum Stuttgart, Stuttgart, Germany

#JW and ESc contributed equally as senior authors.

Correspondence:

K. KAMA - k.kama@klinikum-stuttgart.de

<https://doi.org/10.3324/haematol.2025.287982>

Received: May 21, 2025.

Accepted: December 3, 2025.

Early view: December 11, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

Table S1: Post-Consolidation response rates and subsequent treatments

Response rates after consolidation/maintenance therapy n=32 (%)					
	All patients n=32	HCT-ASCT n=21	CAR T cell therapy n=5	Radiotherapy n=3	Single agent maintenance therapy n=3
ORR	21 (66%)	13 (62%)	4 (80%)	2 (67%)	3 (100%)
CR	11 (34%)	7 (33%)	3 (60%)	1 (33%)	1 (33%)
PR	10 (31%)	6 (29%)	1 (20%)	1 (33%)	2 (66%)
SD	2 (6%)	2 (10%)	0 (0%)	0 (0%)	0 (0%)
PD	4 (13%)	3 (14%)	1 (20%)	0 (0%)	0 (0%)
n/a	5 (16%)	3 (14%)	0 (0%)	1 (33%)	0 (0%)
Subsequent treatments after consolidation/maintenance therapy n=32					
	HCT-ASCT n=21	CAR T cell therapy n=5	Radiotherapy n=3	Single agent maintenance therapy n=3	
No further treatment (n=7)		No further treatment (3)	No further treatment (2)	No further treatment (1)	
Stereotactic radiotherapy (5)		MATRix, allogeneic hematopoietic cell transplantation (1)	Rituximab/Cytarabine/Thiotepa (1)	R-DeVIC, Tafasitamab and Lenalidomide (1)	
Venetoclax/Obinutuzumab, R-DeVIC (3)		Polatuzumab/Ibrutinib, WBRT (1)		MATRix, Tafasitamab and Lenalidomide, WBRT, Temozolomide and Rituximab (1)	
Carboplatin/Pemetrexed (1)					
Ibrutinib, Nivolumab, MATRix, Thiotepa (1)					
Nivolumab, Methotrexate (1)					
Lenalidomide (1)					
Ibrutinib (1)					
Temozolomide, Tafasitamab/Lenalidomide, Rituximab/Methotrexate, allogeneic hematopoietic cell transplantation (1)					

Table S2: Comparison of salvage regimens in relapsed/refractory CNS lymphoma

Regimen	ORR (%)	Median PFS (months)	Grade 3–4 Toxicity (%)	Patients (n)	Reference
R-HD-AraC/TT (high-dose-cytarabine, thiotepa)	56	12.4	79	39	3
Ibrutinib	60-74	4.5–5.3	12	46	5
Lenalidomide	64	6.0	35	14	6
Topotecan	33	2.0	33	27	10
Pemetrexed	55	5.7	63	11	11
Temozolomide	31	2.8	27	36	12
R-GemOx (rituximab, gemcitabine, oxaliplatin)	38	3.2	38	13	13
ICE (ifosfamide, carboplatin, etoposide)	70	3.4	90	96	14
R-DeVIC (this study)	47	2.0	63	100	—